AI Article Synopsis
- Anifrolumab is a drug that blocks a specific receptor (IFNAR1) and is approved for treating moderate-to-severe systemic lupus erythematosus (SLE).
- * In clinical trials, it has shown effectiveness for skin-related lupus issues, even though it's not specifically approved for cutaneous lupus erythematosus (CLE).
- * Ongoing studies aim to assess its effectiveness for different types of lupus and related conditions, while its common side effects include respiratory infections and herpes zoster.
Article Abstract
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ad.2024.10.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Associated Risk of Subacute Cutaneous Lupus Erythematosus: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
J Cutan Med Surg
December 2024
Department of Dermatology, Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus.
Lupus
December 2024
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Background: Patients with cutaneous lupus erythematosus (CLE) can present with one or multiple different subtypes of CLE. There is limited understanding of the prevalence and associated risk factors for having multiple CLE subtype diagnoses.
Objective: This study characterized the frequency and risk factors for having multiple CLE subtypes.
25th National and 11th International Annual Congress on Research and Technology of Iranian Medical Sciences Students, Urmia, Iran, 5-7 September, 2024.
Iran Biomed J
December 2024
Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
B Cell Receptor Repertoire Analysis of the CD21 B Cell Compartment in Healthy Individuals, Patients With Sjögren's Disease, and Patients With Radiographic Axial Spondyloarthritis.
Eur J Immunol
December 2024
Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Article Synopsis
- CD21 B cells are a type of immune cell that show increased numbers in patients with rheumatic diseases, including common autoimmune conditions and autoinflammatory diseases like axial spondyloarthritis.
- Researchers studied the B-cell receptor repertoire using next-generation sequencing to understand the origins and relationships of these CD21 B cells and their development into more mutated forms (like plasmablasts) in patients compared to healthy individuals.
- The findings suggest that expanded CD27CD21 B cells in autoimmune and autoinflammatory patients may play a significant role in contributing to harmful immune responses associated with these diseases.
HMGA1 influence on iron-induced cell death in Tfh cells of SLE patients.
Cell Biol Toxicol
December 2024
Department of Rheumatology and Immunology, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang, 110001, Liaoning Province, China.
The autoimmune disorder known as Systemic Lupus Erythematosus (SLE) exhibits intricate features with abnormal immune responses leading to tissue injury. The generation of antibodies and the disruption of immune regulation heavily depend on the pivotal function of T follicular helper (Tfh) cells. Iron dysregulation is significant in autoimmune diseases, impacting immune cell function and disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!